WordNet

write by means of a keyboard with types; "type the acceptance letter, please" (同)typewrite
a small metal block bearing a raised character on one end; produces a printed character when inked and pressed on paper; "he dropped a case of type, so they made him pick them up"
(biology) the taxonomic group whose characteristics are used to define the next higher taxon
a subdivision of a particular kind of thing; "what type of sculpture do you prefer?"
all of the tokens of the same symbol; "the word `element contains five different types of character"
printed characters; "small type is hard to read"
identify as belonging to a certain type; "Such people can practically be typed" (同)typecast
relating to or having the characteristics of a family; "children of the same familial background"; "familial aggregation"
occurring among members of a family usually by heredity; "an inherited disease"; "familial traits"; "genetically transmitted features" (同)genetic, hereditary, inherited, transmitted, transmissible
having or involving or consisting of more than one part or entity or individual; "multiple birth"; "multiple ownership"; "made multiple copies of the speech"; "his multiple achievements in public life"; "her multiple personalities"; "a pineapple is a multiple fruit"
the product of a quantity by an integer; "36 is a multiple of 9"
a conjugated protein having a lipid component; the principal means for transporting lipids in the blood
writing done with a typewriter (同)typewriting

PrepTutorEJDIC

〈C〉(…の)『型』,タイプ,類型,種類(kind)《+of+名》 / 〈C〉(その種類の特質を最もよく表している)『典型』,手本,模範《+of+名》 / 〈U〉《集合的に》活字;〈C〉(1個の)活字 / 〈U〉(印刷された)字体,活字 / 〈C〉(貨幣・メダルなどの)模様,図柄 / 〈C〉血液型(blood group) / …‘を'タイプに打つ / (…として)…‘を'分類する《+名+as+名(doing)》 / …‘の'型を決める / タイプライターを打つ
家族の,家族特有の / 違伝的な,血統にあらわれる
多数の部分(要素)から成る,複合の,複式の / 倍数

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. LDLコレステロール代謝の遺伝性疾患 inherited disorders of ldl cholesterol metabolism
2. 高トリグリセリド血症患者に対するアプローチ approach to the patient with hypertriglyceridemia
3. Dyslipidemia in children: Management
4. Dyslipidemia in children: Definition, screening, and diagnosis
5. リポ蛋白の分類、代謝、およびアテローム性動脈硬化症における役割 lipoprotein classification metabolism and role in atherosclerosis

English Journal

Vitamin D concentrations in familial combined hyperlipidemia: effects of lipid lowering treatment.

Miñambres I, Sánchez-Quesada JL, Sánchez-Hernández J, Rodríguez J, de Leiva A, Pérez A.AbstractBACKGROUND: Vitamin D deficiency has been linked to several cardiovascular risk factors but information regarding vitamin D concentrations in familial combined hyperlipidemia (FCHL) is lacking. Our objective was to examine vitamin D concentrations in patients with FCHL and to study the effects of lipid-lowering therapy.
Diabetology & metabolic syndrome.Diabetol Metab Syndr.2014 Jan 22;6(1):7. [Epub ahead of print]
BACKGROUND: Vitamin D deficiency has been linked to several cardiovascular risk factors but information regarding vitamin D concentrations in familial combined hyperlipidemia (FCHL) is lacking. Our objective was to examine vitamin D concentrations in patients with FCHL and to study the effects of li
PMID 24450309

Bile acid synthesis precursors in familial combined hyperlipidemia: The oxysterols 24S-hydroxycholesterol and 27-hydroxycholesterol.

Baila-Rueda L1, Mateo-Gallego R2, Jarauta E2, de Castro-Orós I2, Bea AM2, Cenarro A2, Civeira F2.Author information 1Unidad de Lípidos and Laboratorio de Investigación Molecular, Hospital Universitario Miguel Servet, Instituto Aragonés de Ciencias de la Salud (I+CS), Zaragoza, Spain. Electronic address: lbaila.iacs@aragon.es.2Unidad de Lípidos and Laboratorio de Investigación Molecular, Hospital Universitario Miguel Servet, Instituto Aragonés de Ciencias de la Salud (I+CS), Zaragoza, Spain.AbstractFamilial combined hyperlipidemia (FCHL), the most common inherited disorder of lipid metabolism is characterized by increasing cholesterol synthesis precursors due to hepatic overproduction of cholesterol. The bile acids synthesis pathway has not been previously studied in FCHL. The aim of this work was to study the oxysterol levels which are involved in the bile acids synthesis from cholesterol in FCHL. Clinical parameters and subclinical atherosclerosis were studied in a total of 107 FCHL patients and 126 normolipidemic controls. Non cholesterol sterols (desmosterol and lanosterol) and oxysterols (27-hydroxycholesterol and 24S-hydroxycholesterol) were measured by high performance liquid chromatography tandem mass spectrometry. Desmosterol and lanosterol, markers of cholesterol synthesis, had a positive correlation with BMI and apo B. However, no correlation was found for 24S-hydroxycholesterol and 27-hydroxycholesterol, precursors of bile acids, with these clinical parameters. Only 27-hydroxycholesterol had a positive correlation with apo B, ρ=0.204 (P=0.037). All oxysterol levels were higher in FHCL as compared to normal controls. A total of 59 FCHL subjects (59%) presented values of 24S-hydroxycholesterol above the 95th percentile of this oxysterol in the control population. All oxysterols showed no association with fat mass in contrast with non-cholesterol sterols. FCHL subjects with oxysterol overproduction had less carotid intima media thickness (cIMT), which suggests less atherosclerosis in these subjects. In summary, our data indicate that high oxysterol levels might be good markers of FCHL, unrelated to fat mass, and may exert a protective mechanism for cholesterol accumulation.
Biochemical and biophysical research communications.Biochem Biophys Res Commun.2014 Jan 6. pii: S0006-291X(13)02202-X. doi: 10.1016/j.bbrc.2013.12.131. [Epub ahead of print]
Familial combined hyperlipidemia (FCHL), the most common inherited disorder of lipid metabolism is characterized by increasing cholesterol synthesis precursors due to hepatic overproduction of cholesterol. The bile acids synthesis pathway has not been previously studied in FCHL. The aim of this work
PMID 24406166

Antibodies to human angiopoietin-like protein 3: a patent evaluation of WO2012174178.

Nakajima K, Kobayashi J.Author information Gunma University, Graduate School of Health Sciences , Maebashi , Japan.AbstractThe patent WO2012174178 claims the effect of a fully human antibody or antigen-binding fragment of a human antibody which specifically binds and neutralizes, inhibits, blocks, abrogates, reduces or interferes with the activity of human angiopoietin-like protein 3 (hANGPTL3). The effects of human anti-hANGPTL3 mainly inhibit lipoprotein lipase activity and decrease triglyceride levels. In addition, it reduces plasma TC and high-density lipoprotein cholesterol in normal mice and mice with hyperlipoidemia and mimics the plasma profile of human familial combined hypolipidemia. The antibodies are useful in treating diseases or disorders associated with ANGPTL3, such as hyperlipidemia, hyperlipoproteinemia and other dyslipidemias. Furthermore, the anti-hANGPTL3 antibodies can be administered to a subject to prevent or treat abnormal lipid metabolism which causes or enhances the induction of cardiovascular diseases.
Expert opinion on therapeutic patents.Expert Opin Ther Pat.2014 Jan;24(1):113-9. doi: 10.1517/13543776.2013.842555. Epub 2013 Oct 5.
The patent WO2012174178 claims the effect of a fully human antibody or antigen-binding fragment of a human antibody which specifically binds and neutralizes, inhibits, blocks, abrogates, reduces or interferes with the activity of human angiopoietin-like protein 3 (hANGPTL3). The effects of human ant
PMID 24094083